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Abstract
Background: Bee venom acupuncture (BVA), a novel type of acupuncture therapy in which purified bee venom is
injected into the specific acupuncture point on the diseased part of the body, is used primarily for relieving pain
and other musculoskeletal symptoms. In the present study, therapeutic potential of BVA to improve atopic
dermatitis, a representative allergic dysfunction, was evaluated in the mouse model of trimellitic anhydride (TMA)-
induced skin impairment.
Methods: Mice were treated with 5 % TMA on the dorsal flank for sensitization and subsequently treated with 2 %
TMA on the dorsum of both ears for an additional 12 days after a 3-day interval. From the 7th day of 2 % TMA
treatment, bilateral subcutaneous injection of BV (BV, 0.3 mg/kg) was performed daily at BL40 acupuncture points
(located behind the knee) 1 h before 2 % TMA treatment for 5 days.
Results: BVA treatment markedly inhibited the expression levels of both T helper cell type 1 (Th1) and Th2
cytokines in ear skin and lymph nodes of TMA-treated mice. Clinical features of AD-like symptoms such as ear skin
symptom severity and thickness, inflammation, and lymph node weight were significantly alleviated by BV
treatment. BV treatment also inhibited the proliferation and infiltration of T cells, the production of Th1 and Th2
cytokines, and the synthesis of interleukin (IL)-4 and immunoglobulin E (IgE)—typical allergic Th2 responses in
blood. The inhibitory effect of BVA was more pronounced at BL40 acupoint than non-acupuncture point located at
the base of the tail.
Conclusions: These results indicate that BV injection at specific acupuncture points effectively alleviates AD-like skin
lesions by inhibiting inflammatory and allergic responses in a TMA-induced contact hypersensitivity mouse model.
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Background
In traditional Oriental medicine, bee venom acupuncture
(BVA), a peculiar type of acupuncture, has been used to
relieve pain and to treat various chronic inflammatory
diseases in humans. It exerts not only pharmacological
effects due to its various bioactive components, but also
exerts an acupuncture effect by mechanical stimulation
of acupuncture points [1].
BV seems to be much like a double-edged sword. In
traditional Oriental medicine, BV therapy relieves pain
and inflammation in various acute or chronic diseases
[2]. On the other hand, it also induces a systemic or
local allergic response, with fever, pain, and itching,
sometimes leading to anaphylaxis [3]. According to clin-
ical reports of BVA therapy, subcutaneous or intramus-
cular injection of BV often causes instant pain and
inflammation around the injection site, as well as relieving
pain and inflammation [4]. It has even been argued by
Oriental physicians treating some musculoskeletal and
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immunological diseases using BV therapy that the greater
the allergic response the better therapeutic effect is [5].
A growing number of studies provide compelling evi-
dence for the anti-inflammatory effects of BVA in sev-
eral animal pain models. For example, BVA can inhibit
formalin-induced pain and carrageenan-induced in-
flammation in rat models [6, 7]. Recently, BV and its
constituent, melittin, were reported to possess anti-
inflammatory, antinociceptive, and anticancer effects,
and also have a therapeutic effect against bacterial diar-
rhea in piglets [8–11]. BVA has also been used to re-
lieve arthritic pain and edema in Korean traditional
medicine [12]. Despite the many clinical and animal
studies elucidating the medicinal effects of BVA in vari-
ous pain and inflammatory diseases, there have been
few studies of BVA as an alternative therapy for atopic
diseases. Because BV sometimes induces systemic ana-
phylactic responses when injected in excessive amounts,
it is reasonable to expect that diseases caused by immuno-
logical hypersensitivity, including atopic dermatitis, can be
treated by honey bee venom, which is well known to be
an inflammatory agent as well as an allergen. To the best
of our knowledge, this is the first study to elucidate the
medicinal effect of BV on atopic dermatitis-like skin dis-
ease in mice.
In this study, an atopic mouse model of allergen-
induced contact hypersensitivity was used to assess BVA
therapy for human atopic dermatitis. In contrast to other
spontaneous (NC/Nga) transgenic and knockout mouse
models, this model is simple to develop and its atopic
symptoms are highly reproducible. Trimellitic anhydride
(TMA), used in this study as an allergen, is a known re-
spiratory sensitizer that induces T cell-dependent con-
tact hypersensitivity in mice, eliciting eosinophil and T
cell infiltration, T helper cell type 2 (Th2) cytokine pro-
duction, and IgE release [13]. In the TMA-induced
atopic model, mice are first sensitized on flank skin with
TMA, and then T cell-dependent skin inflammation is
induced by topical challenge with TMA on the dorsal
surfaces of the ears 1 week after sensitization. The se-
verity of atopic inflammation can easily be evaluated
by observing ear appearance and measuring ear thick-
ness. The effects of TMA-induced skin inflammation
on the cutaneous cytokine profile, infiltration of im-
mune cells, and serum IgE levels have been previously
studied [14–16].
Although anti-inflammatory steroids are a conven-
tional therapy for atopic dermatitis, there are however
several concerns with this therapy, especially with long-
term use. Mid- to high-potency steroids are contraindi-
cated for use on the body and in intertriginous areas
because of their side effects, including skin atrophy,
hypopigmentation, striae, secondary infection, and acne
[17]. Alternative treatments using BV are of particular
interest, because BV seems to be effective without caus-
ing severe adverse effects like those that are often ob-
served with steroid therapy.
For this purpose, we investigated the medicinal effect
of BVA on atopic dermatitis using a TMA-induced con-
tact hypersensitivity dermatitis mouse model. BVA injec-
tion was performed at the BL40 acupoint, which is
known to cool down the body in Korean traditional
medicine [18]. In addition to clinical observation, we
also investigated the infiltration of immune cells in ear
tissue by histological staining, serum IgE levels by
enzyme-linked immunosorbent assay (ELISA), and T cell
cytokine profiles in ears and lymph nodes using the Bio-
Plex® suspension array system.
Methods
Animals
Male BALB/c mice weighing 28–30 g (10 weeks old)
were purchased from Samtaco Co. (Osan, Korea). The
mice were housed in a limited-access rodent facility with
up to five mice per polycarbonate cage. They were
housed in an air-conditioned animal room with a 12 h
light/dark cycle (08:00–20:00 h light, 20:00–08:00 h
dark) at 23 ± 2 °C and with 50 ± 10 % humidity. Mice
were provided with a standard laboratory diet and water
ad libitum. The animal experiments were conducted in
accordance with the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 80–23, re-
vised in 1996), and were approved by the Kyung Hee
University Institutional Animal Care and Use Committee.
All animal experiments began at least 7 days after the
animals arrived.
Chemicals and drugs
All chemicals including TMA (98 %), bee venom, pred-
nisolone, isopropyl myristate (98 %), dimethylsulfoxide,
ethanol and corn oil were purchased from Sigma-
Aldrich Co. (St. Louis, MO, USA). TMA was dissolved
in a mixed solvent of acetone (Merck, Darmstadt,
Germany) and isopropyl myristate (4:1, v/v) immediately
before use. Bee venom was dissolved in saline, and pred-
nisolone was dissolved in a mixed solvent of dimethyl-
sulfoxide, ethanol and corn oil (5:3:92, v/v/v).
Development of atopic dermatitis
A modified version of a protocol described by Schneider
et al. was used to induce atopy-like skin dermatitis in
mice [19]. Mice were first sensitized with 50 μL of 5 %
TMA on the shaved dorsal flank skin on day 0. After an
interval for 3 days, the animals received 10 μL of 2 %
TMA once a day from days 3 to 14 on both sides of
both ears. The mice were sacrificed under anesthesia
with pentobarbital on the last day of the experiment. At
autopsy, blood was collected from the retro-orbital
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plexus, and both ears and auricular lymph nodes were
excised.
Experimental groups
The mice were randomly divided into five experimental
groups of ten animals each as follows: non-treated naive
group (NOR, n = 10), vehicle-treated & TMA-treated
atopic group (AD, n = 10), BV-treated at BL40 acupoint
& TMA-treated atopic group (AD + BVA, n = 10), BV-
treated at non-acupoint & TMA-treated atopic group
(AD + BVNA, n = 10), and prednisolone-treated & TMA-
treated atopic group (AD + PRE, n = 10). Prednisolone
(30 mg/kg, p.o.) was used as a positive control.
BVA and drug treatments
To determine the optimum conditions for BV injection,
changes in skin temperature at the injection site were
analyzed under conditions of subcutaneous, intradermal,
and intramuscular injection of BV. BV (0.3 mg BV/kg
body weight) was injected into the mid-back after hair
removal, and the temperature at the injection site was
measured using an infrared thermometer (HuBDIC
Thermofinder (FS-300), Beauty Korea World Co., Ltd.,
Seoul, Korea). Each type of BV injection was performed
in at least three mice, and temperature measurement was
repeated three times per injection site per time point.
Daily treatment with BV and prednisolone was per-
formed 1 h before TMA challenge on days 9 to 14 (a total
of six times) (Fig. 1). For BVA treatment, the mice were
gently immobilized with hands, and 20 μL BV solution
(0.3 mg/kg) was injected bilaterally at a depth of 1 mm at
the BL40 acupoints, located in the center of the popliteal
crease between the tendons of the biceps femoris and
semitendinosus muscles on both legs, using a 1 mL insulin
syringe (needle gauge 26; BD Biosciences Co., CA, USA).
A non-acupuncture point at the base of the tail was used
as a control. The needles were removed from the acupoints
immediately after BV injection. As a positive control, pred-
nisolone, a glucocorticoid prodrug, was administered orally
to mice at a dose of 30 mg/kg body weight.
Scoring of ear skin manifestations
The ear skin of mice in each experimental group was
photographed using a digital camera (Canon 20D; Canon
Inc., Tokyo, Japan) to analyze changes in atopic symp-
toms and clinical appearance of the ear skin and tissues.
The severity of atopic dermatitis was macroscopically
assessed, and scored in a blinded fashion every 2 days
starting from the day after the first 5 % TMA challenge,
according to the protocol of Shin HK et al. [20]. Atopic
symptoms of ear skins were evaluated by scoring scaling
and dryness, hemorrhage and excoriation, and edema
and redness, and by then calculating the sum of the indi-
vidual symptom scores for both ears, graded as 0 (no
symptoms), 1 (mild), 2 (moderate), or 3 (severe). The
total score for each animal ranges from 0 to 9.
Measurements of ear thickness and auricular lymph node
weight
Ear thickness and auricular lymph node weights of all 10
mice in each experimental group was measured. Ear
thickness was measured with a dial thickness gauge
(Ozaki Seisakusho Co., Tokyo, Japan), and the weight of
the auricular lymph node was measured with a digital
balance (Mettler-Toledo Inc., Columbus, OH, USA).
ELISA of immune mediators
After scoring of ear skin manifestation, blood samples
were rapidly collected from all 10 mice in each experi-
mental group under anesthesia on the day of killing via
the retro-orbital plexus using a capillary pipette. Serum
was obtained from the blood samples by centrifugation
at 6500 rpm for 20 min, and was stored at −70 °C until
use. Serum IL-4 and IgE levels were measured using an
ELISA kit (R&D Systems Inc., MN, USA and Bethyl La-
boratories Inc., TX, USA, respectively). After coating the
inner surfaces of microplate wells with each antibody at
4 °C overnight, serum samples (50 μL, 3-fold dilution)
were dispensed into the wells and incubated for 1 h.
After washing the plate twice, 100 μL avidin-horseradish
peroxidase (HRP)-conjugated antibody was added. After
another wash, tetramethylbenzidine (TMB) solution was
added, and the plate was incubated for 30 min in the
dark. After stopping the reaction with 50 μL stop solu-
tion, the absorbance at 450 nm was measured using an
ELISA reader (Multi-Read 400; Authos Co., Austria).
Fig. 1 Experimental schedules for developing TMA-induced atopic dermatitis and treating with BV in mice. TMA, trimellitic anhydride; BV, bee venom
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RT-PCR analysis of immune mediators
For this, 5 mice from each group (n = 10) were deeply
anesthetized with sodium pentobarbital (50 mg/kg, i.p.),
and their ear tissues and auricular lymph nodes were
quickly collected. Total RNA was isolated from each tis-
sue sample of ear or lymph node. After excision, tissue
samples were quickly stored at −80 °C until use. Total
RNA was isolated using TRIzol® reagent (Gibco BRL
Co., MD, USA). Complementary DNA (cDNA) was syn-
thesized from total RNA with reverse transcriptase
(Takara Co., Shiga, Japan). The expression levels of
mRNAs were determined by PCR analysis using cDNA as
the template. PCR was performed using a PTC-100
programmable thermal controller (MJ Research Co., MA,
USA). Primers were designed based on published mRNA
sequences using Primer3 primer selection software (White-
head institute for Biomedical Research, Cambridge, MA:
http://biotools.umassmed.edu/bioapps/primer3_www.cgi).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as a housekeeping gene. PCR products were separated
on 1.2 % agarose gels and stained with ethidium bromide.
Subsequently, band densities were analyzed using an image
analysis system (i-Max™; Core Bio System Co., Ltd., Seoul,
Korea). Relative gene expression was determined by calcu-
lating the relative band intensity for each gene compared
to GAPDH. Table 1 provides the primer sequences and an-
nealing conditions for PCR.
Histology and immunohistochemistry
Five mice from each group (n = 10) were deeply anesthe-
tized with sodium pentobarbital (50 mg/kg, i.p.), and
their ear tissues were quickly collected. Each ear tissue
was embedded in paraffin, and cut into 6 μm-thick sec-
tions using a rotatory microtome (Finesse 325; Thermo
Shandon Co., UK). The sections were deparaffinized
before staining. To demonstrate morphologic changes
and eosinophil infiltration, sections were stained with
hematoxylin (Merck, Darmstadt, Germany) and 1 %
eosin (Sigma-Aldrich Co.) [21]. Staining with toluidine
blue (Merck) was performed for mast cell detection.
For immunohistochemistry, the other half of each ear
was embedded in paraffin and cut into 6 μm-thick sec-
tions. The sections were deparaffinized before immuno-
histochemistry. Slides were incubated overnight at 4 °C
in a primary antibody solution containing anti-mouse
cluster of differentiation (CD)4 and anti-mouse CD8
rabbit antibodies (1:200 dilution; Novus Biologicals Co.,
Littleton, USA), after which they were incubated with
anti-rabbit secondary antibody (1:500 dilution; Vector
Laboratories Inc., CA, USA). Next, the slides were
treated with a Vectastain™ Elite ABC kit (Vector
Laboratories Inc.). Immunopositive spots on the slides
were developed using diaminobenzidine (DAB) as a col-
orimetric substrate. A cover slip was then placed over
the tissue. All slides were examined at 100× magnifica-
tion using a microscope equipped with a digital camera
(BX51; Olympus Co., Tokyo, Japan) and DP2-BSW ana-
lysis software (Olympus Co).
Bio-Plex analysis of Th1 and Th2 cytokines in auricular
lymph node tissue
Five mice from each group (n = 10) were deeply anesthe-
tized with sodium pentobarbital (50 mg/kg, i.p.), and
their auricular lymph nodes were quickly collected.
Cytokine assay of each auricular lymph node was per-
formed using the Bio-Plex Mouse Cytokine 8-Plex Panel
(one 96-well plate) (Bio-Rad Laboratories, Inc., CA,
USA) according to the manufacturer’s instructions. This
is a multiplex bead-based assay (xMAP Technology) in-
volving diverse matrices that are designed to simultan-
eously quantitate many cytokines in a small amount of
tissue. The assay was performed as follows. The wells of
a 96-well filter plate were pre-wetted with 100 μL Bio-
Plex assay buffer. Multiplex bead working solution was
vortexed for 15–20 s at medium speed, and 50 μL solu-
tion was added to each well. The buffer was removed by
vacuum filtration and 100 μL fresh Bio-Plex wash buffer
was added to each well. The buffer was again removed
by vacuum filtration. This step was repeated once again
and 50 μL diluted standard or sample was added to each
well. The plate was covered with aluminum foil and
shaken at 1100 rpm for 30 s, and then shaken at
Table 1 Nucleotide sequences of primers and operating condition for PCR analysis
Gene Nucleotide sequence Operating condition
GAPDH sense 5′-AACTTTGGCATTGTGGAAGG-3′ 94 °C, 30s
58 °C, 30s








T thymine, A adenine, C cytosine, G guanine, GAPDH glyceraldehyde-3-phosphate dehydrogenase, IL interleukin, TNF tumor necrosis factor
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300 rpm for 90 min at room temperature. Next, the
plate was washed three times with 100 μL Bio-Plex wash
buffer. After vacuum filtration, vortexed working solu-
tion of Bio-Plex Detection Antibody (25 μL) was gently
added to each well, and the plate was shaken as de-
scribed above and washed three times with Bio-Plex
washing buffer. Vigorously vortexed 1× streptavidin-
peroxidase solution (50 μL) was added to each well, and
the plate was shaken at 1100 rpm for 30 s, and sub-
sequently at 300 rpm for 10 min. After three washes,
the beads in each well were resuspended with 125 μL
Bio-Plex assay buffer, and the plate was shaken at
1100 rpm for 30 s. Beads were read using Bio-Plex
Manager® software.
Statistical analysis
All measurements were performed by an independent
investigator blinded to the experimental conditions.
Results in figures are expressed as mean ± standard
error of means (SEM). Experimental data were ana-
lyzed by one-way ANOVA using SPSS version 13.0
(IBM, Chicago, USA). Statistical differences among
groups were further analyzed using Tukey’s post hoc
test. All p values less than 0.05 were considered sta-
tistically significant.
Results
Clinical manifestation of TMA-treated atopy-like ear skin
lesions
Repeated application of TMA to mouse ear skins in-
duced atopy-like skin lesions with typical atopic symp-
toms such as erythema, excoriation, erosion, scaling, and
dryness (Fig. 2a). The severity of atopic disease was eval-
uated by individually scoring the symptoms (skin dry-
ness, hemorrhage and excoriation, and edema and
redness). The atopic dermatitis-like skin symptoms
began to be observed on day 3 during the 5 % TMA
challenge period, and showed maximum exacerbation
on day 9 during the 5 % TMA challenge period, as
shown in Fig. 2b. BV treatment was started on day 9,
when atopy-like symptoms reached their peak. Daily BV
treatment at the BL40 acupoint markedly alleviated the
symptoms without apparent initial signs of acute inflam-
mation or hypersensitivity due to BV injection. There
were also no inflammation responses in the skin tissues
around the BL40 acupoint after BV injection (data not
shown). The therapeutic efficacy of BVA at BL40 was
similar to that of prednisolone, a steroid drug, which
was used as a positive control in the present study.
Acupuncture stimulation at a non-acupuncture point
(AD+ BVNA) showed no therapeutic effect on atopic
dermatitis-like symptoms in mice.
Fig. 2 Representative images (a) of mouse ears and scoring graph (b) in the NOR, AD, AD + BVA, AD + BVNA and AD + PRE groups. The graph
indicates time-course severities of atopic dermatitis by scoring each image between 0 and 9 points depending on the following skin
symptoms: scaling and dryness, hemorrhage and excoriation, and edema and redness. The arrow indicates the initiation of BV or prednisolon
treatment. ***p < 0.001 vs. the NOR group; ##p < 0.01, ###p < 0.001 vs. the AD group
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Changes in ear thickness and auricular lymph node
weight
In addition to morphological changes in inflamed ear
skin, repeated application of TMA to the ear skin also
induced a significant increase in ear thickness in mice
(Fig. 3a). Mouse ear thickness increased about 3-fold by
TMA treatment, and BV injection at acupoint BL40 sig-
nificantly suppressed the increase in ear thickness on
day 14 (p < 0.001). The medicinal efficacy of BVA treat-
ment on reducing ear thickness in the AD + BVA group
was similar to that of prednisolone in the AD + PRE
group. Although BVA stimulation at a non-acupuncture
point also reduced ear thickness, the effect was negli-
gible, as compared to that of acupuncture stimulation at
BL40. As shown in Fig. 3b, repeated treatments of TMA
in the AD group induced a significant increase in auricu-
lar lymph node weight.
Auricular lymph node weight on day 14 after TMA
treatment increased about 13-fold. Whereas BV injec-
tion at a non-acupuncture point on the tail had no effect
on the increase in auricular lymph node weight, the
same treatment at acupoint BL40 significantly reduced
auricular lymph node weights (p < 0.001). Moreover, the
decrease in auricular lymph node weight in the AD +
BVA group was similar to that in the AD + PRE group, a
positive control group.
Changes of serum IL-4 and IgE levels
Serum levels of IgE and IL-4, which are increased in
most patients with atopic dermatitis, were determined in
the TMA-induced mouse model as a parameter for
humoral (Th2) responses [22, 23]. In the present study,
as shown in Fig. 4, serum levels of IL-4 and IgE were el-
evated about 3.7-fold and 6.5-fold, respectively, in the
AD group on day 14 after TMA treatment. The secre-
tion profiles of these factors are very similar to the pro-
file for eosinophil activation, which plays a crucial role
in aggravating atopic dermatitis symptoms [24]. BV
injection at acupoint BL40 significantly suppressed the
elevation of IL-4 and IgE levels (p < 0.001) on day 14.
Notably, the suppressive effect of BV treatment at acu-
point BL40 on serum IL-4 level in the AD + BVA group
was comparable to that in the AD + PRE group. BV in-
jection at a non-acupuncture point on the tail did not
reduce serum IgE and IL-4 levels.
Histological changes of ear skin tissues
Morphological changes in inflamed skin layers and cuta-
neous infiltration of immune cells were characterized by
histochemical techniques (Fig. 5). Inflammatory re-
sponses such as thickening of ear skin including dermis
and epidermis, edema and epidermal hyperplasia, which
leads to massive infiltration of various immune cells
from the blood vessels into the dermis layers, were ob-
served in coronal sections of ear skin tissues stained
with hematoxylin and eosin in the AD group
(Fig. 5a1-a5). BV treatment at acupoint BL40 signifi-
cantly inhibited these inflammatory changes in both
the epidermis and dermis, although its suppressive ef-
ficacy was lower than that of prednisolone. BVA ther-
apy at a non-acupuncture point had no significant
effect on histochemical changes in inflammation.
Of the pathogenic features of blood in atopic derma-
titis patients, such as IgE, eosinophils, and mast cells,
the role of mast cells is demonstrated by increases in cell
numbers and mast cell activation in atopic dermatitis le-
sions [25]. In the present study, mast cells in the dermis
in mice with TMA-induced atopy-like dermatitis were
analyzed by toluidine blue staining (Fig. 5b1-b5). Topical
application of TMA markedly increased mast cell infil-
tration in the epidermis and dermis of ear skin in the
AD group. BV treatment at acupoint BL40 significantly
alleviated the TMA-induced infiltration of mast cells.
Its therapeutic efficacy was similar to that of prednisol-
one. BV stimulation at a non-acupuncture point had no
such effect.
Fig. 3 Ear thickness (a) and lymph node weights (b) of the mice in the NOR, AD, AD + BVA, AD + BVNA and AD + PRE groups. ***p < 0.001 vs. the
NOR group; #p < 0.05, ###p < 0.001 vs. the AD group
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Fig. 4 Serum levels of IL-4 (a) and IgE (b) in the NOR, AD, AD + BVA, AD + BVNA and AD + PRE groups using an ELISA. IL, interleukin; IgE,
immunoglobulin E; ELISA, enzyme-linked immunosorbent assay. ***p < 0.001 vs. the NOR group; #p < 0.05, ###p < 0.001 vs. the AD group
Fig. 5 Histological images and graphs indicating relative percentage of CD4- and CD8-immunopositive cells of the ear sections. Ear sections in each
group were stained with hematoxylin and eosin (a1-a5), toluidine blue (b1-b5), anti-mouse CD4 IgG (c1-c5) and anti-mouse CD8 IgG (d1-d5). Black
scale bar indicates 100 μm (100× magnification). Black thick lines in the images of H-E staining indicate the thickness of ear skins. Small white squares
(200×) in the centers of immunohistological staining images (c2 & d2 of AD group) are magnified in the lower left corners to observe CD4- and CD8-
positive cells infiltrated into the skin tissues. The representative CD4- and CD8-immunopositive cells were indicated by black arrows in indicated in
small white squares in C2 and D2, respectively. The numbers of CD4- and CD8-immunopositive cells in the fixed area of the images are depicted in
the bar graphs e and f, respectively, below the histological images. IgG, immunoglobulin G; CD, cluster of differentiation. ***p < 0.001 vs. the NOR
group; #p < 0.05, ##p < 0.005 and ###p < 0.001 vs. the AD group
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To investigate cutaneous infiltration of allergen-specific
T cells, CD4+, and CD8+ T cells were analyzed in ear
skin tissues using an immunohistochemical technique
(Fig. 5c1-c5 and d1-d5). In the present study, CD4+ T
cell infiltration was predominantly observed in the
dermis and CD8+ T cells were mainly localized in the
epidermis in the AD group, as shown in Fig. 5c2 and
d2. BV injection at acupoint BL40 significantly inhib-
ited the infiltration of CD4+ and CD8+ T cells caused
by repeated application of TMA (Fig. 5e and f ). Its
therapeutic efficacy was similar to that of prednisol-
one. BV stimulation at a non-acupuncture point had
no effect of suppressing the infiltration of CD8+ T
cells even though there was little effect of non-
acupoint stimulation in case of CD4+ T cells.
RT-PCR analysis of cytokine mRNA expression in ear skin
and auricular lymph nodes
To investigate Th1 and Th2 cytokine gene expression,
mRNA levels of cytokines such as tumor necrosis factor
(TNF)-α, IL-1β, and IL-4 were determined in ear and
auricular lymph node tissue homogenates using RT-PCR
(Fig. 6). TNF-α and IL-1β were selected as Th1 inflam-
matory cytokines for the auricular lymph node and ear,
respectively, and IL-4 was selected as a representative
Th2 cytokine for both tissues. In ear tissues, mRNA ex-
pression of IL-1β and IL-4 showed similar patterns: re-
peated application with TMA induced significant
increases in the expression of IL-1β and IL-4 mRNAs,
and BV treatment at acupoint BL40 significantly sup-
pressed the TMA-induced mRNA expression of both cy-
tokines. The suppressive effect of BV treatment at
acupoint BL40 was similar to that of prednisolone. In all
cases, BV stimulation at a non-acupuncture point
showed weaker suppressive effects even though suppres-
sion levels were insignificant than that in the BL40 acu-
point stimulation except IL-1β.
In auricular lymph node tissues, topical application of
TMA induced significant increases in the expression of
TNF-α and IL-4 mRNAs. BV treatment at acupoint
BL40 significantly suppressed TMA-induced mRNA ex-
pression of both cytokines in the lymph node. In the
case of TNF-α, application of BVA to a non-
acupuncture point had a non-significant suppressive ef-
fect on mRNA expression of the cytokines.
Bio-Plex analysis of Th1 and Th2 cytokine production in
the auricular lymph node
When allergens including TMA activate naïve anti-
allergen T cells in mice, lymph node IL-4 concentrations
Fig. 6 The mRNA expression levels of IL-1β (a) and IL-4 (b) in ear tissue (E), and TNF-α (c), and IL-4 (d) in auricular lymph node (LN) in mice. IL,
interleukin; TNF, tissue necrosis factor. **p < 0.01, ***p < 0.001 vs. the NOR group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the AD group
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are abruptly increased, and subsequently induce naïve T
cells to differentiate into Th2 effector cells. These Th2
cells then secrete Th2 cytokines to promote isotype
switching to IgE in activated B cells, and to influence
other immune cells responding to the allergen [26, 27].
In the present study, the secretion profiles of cutaneous
cytokines in auricular lymph node tissues were measured
at the protein level using the Bio-Plex suspension array
system (Fig. 7). IL-2 (a), IL-12 (b), interferon (IFN)-γ (c)
and TNF-α (d) were quantified as Th1 inflammatory cy-
tokines, and IL-5 (e), IL-10 (f ), granulocyte-macrophage
colony-stimulating factor (GM-CSF) (g) and IL-4 (h) as
Fig. 7 Analysis of the levels of cytokines such as IL-2(a), IL-12(b), IFN-γ(c), IL-5(d), IL-10(e), GM-CSF(f), TNF-α(g) and IL-4(h). The analysis was
performed using the Bio-Plex® suspension array system, in the auricular lymph node in mice. GM-CSF, granulocyte macrophage colony-stimulating
factor; IFN, interferon; IL, interleukin; TNF, tissue necrosis factor. *p < 0.05, ***p < 0.001 vs. the NOR group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. the
AD group
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Th2 cytokines in auricular lymph node tissues. Repeated
challenge with TMA caused significant increases in the
secretion of all cytokines, regardless of Th1/Th2 pheno-
type. Among the cytokines examined, IL-5 showed the
weakest induction after repeated topical application of
TMA, and IL-4 showed the strongest. BV treatment at
acupoint BL40 significantly suppressed the TMA-
induced increases in the secretion of these cytokines. BV
treatment at a non-acupuncture point had a little sig-
nificant suppressive effect on protein expression of the
cytokines such as IFN-γ, IL-10 and GM-CSF while
there were also non-significant effects of suppression in
cases of IL-2, IL-4, IL-5 and IL-12 expression. In the
AD + BVA group, the protein expression levels of the
Th1 cytokines IL-2, IL-12, IFN-γ, and TNF-α decreased
to 2.1 ± 0.17 (p < 0.01, AD group vs. AD + BVA group),
2.12 ± 0.13 (p < 0.05, AD group vs. AD + BVA group),
2.48 ± 0.21 (p < 0.001, AD group vs. AD + BVA group),
and 5.04 ± 1.76 (p < 0.01, AD group vs. AD + BVA
group), respectively, from 3.17 ± 0.12, 3.88 ± 0.1, 4.43 ±
0.27, and 19.0 ± 2.5 in the AD group. In the AD + BVA
group, the protein expression levels of the Th2 cytokines
IL-5, IL-10, GM-CSF, and IL-4 decreased to 0.13 ± 0.1,
2.23 ± 0.12 (p < 0.001, AD group vs. AD + BVA group),
0.33 ± 0.15 (p < 0.05, AD group vs. AD + BVA group), and
57.23 ± 2.7 (p < 0.001, AD group vs. AD + BVA group), re-
spectively, from 0.5 ± 0.5, 3.87 ± 0.03, 1.26 ± 0.17, and
81.64 ± 4.72 in the AD group. The therapeutic efficacy of
BVA treatment at suppressing the secretion of TNF-α and
IL-2 (Th1 cytokines), and IL-4, IL-10, and GM-CSF (Th2
cytokines), was similar to that of prednisolone.
Discussion
There have been few objective ways to determine the
optimum dose of BV in clinics and animal studies. Ac-
cording to unpublished reports from Oriental clinics,
the best outcome with BVA can be achieved with the
maximum dose of BV, with substantial heat and pain
around the injection site. Because the injection of exces-
sive amounts of BV sometimes induces anaphylactic
symptoms, physicians using BVA gradually increase its
dose according to the patient’s verbal response to treat-
ment. One possible way to objectively optimize the injec-
tion method or daily dose is to measure the skin
temperature around the BV injection site. We measured
the temperature at the injection site after intradermal,
subcutaneous, and intramuscular injection of BV into the
backs of mice, and eventually adopted subcutaneous injec-
tion for BVA in this study (Additional file 1: Figure S1).
In the present study, BV therapy was used to treat
atopic dermatitis, a typical allergic disease in which the
intrinsic immune system is over-activated in response to
various environmental factors. To investigate anti-
inflammatory activities of BVA, we produced chronic
TMA-induced T cell-dependent skin inflammation in
mouse ears using the protocol of Schneider et al. [19]. In
this model, the repeated challenge of ear skin with 2 %
TMA for 12 days after one-shot sensitization with 5 %
TMA on day 0 caused atopic dermatitis-like skin symp-
toms, such as increased skin thickness, change in skin
morphology, and infiltration of immune cells [28]. It is
widely accepted that eosinophils, mast cells, and CD4+ T
cells mainly infiltrated the dermis and CD8+ T cells
mainly infiltrated the epidermis [29]. And our results
were also coincident with the previous findings. From
histological findings that the majority of skin-infiltrating
T cells in active atopic dermatitis lesions in humans are
CD4+ T cells, CD4+ T cells are considered pivotal to the
development of eczema and skin eosinophilic inflamma-
tion, because they produce a mixed pattern of Th1 and
Th2 cytokines in the pathological development of atopic
dermatitis [26]. CD8+ T cells are also dominant effector
cells. They are responsible for allergen-induced skin in-
flammation, and thus their infiltration is required for
the development of atopic dermatitis-like lesions and
the initiation of mixed Th1/Th2 skin inflammation in
rodent models.
Local lymph node weight is also increased by topical
application of allergens including TMA or haptens such
as dinitrofluorobenzene, 2,4-dinitrochlorobenzene, and
trinitrochlorobenzene [30]. Hence, local lymph node
weight was recently validated as a main index of allergic
and immune responses in murine models. In the present
study, lymph node weight also significantly increased
after repeated challenge of ear skin with TMA (Fig. 3b).
Repeated topical application of allergens or haptens
causes significant increases in blood IgE and IL-4 levels in
a rodent allergy model [23, 31]. Topical exposure of hap-
tens including dinitrofluorobenzene, 2,4-dinitrochloroben-
zene (DNCB), and trinitrochlorobenzene (TNCB) also
developed severe contact hypersensitivity in the mice.
However, unlike allergens including TMA, the signifi-
cant increases in eosinophil and T-cell infiltration, Th2
cytokine production and IgE levels were not observed
in the serum of these hapten-induced hypersensitivity
animal models, although a minor increase was reported
previously [32].
In the present study, TMA treatment directly triggered
a T cell-mediated contact hypersensitivity reaction and
also caused distinct changes in the innate and adaptive
immune systems, primarily indicated by increases in the
secretion of Th1 and inflammatory cytokines, and the
production of Th2 cytokines and IgE, respectively.
Serological and tissue investigations also showed an in-
creased serum IgE level and Th2 cytokine dominance in
the serum, ear skin, and auricular lymph node, despite
the simultaneous dominance of Th1 cytokines such as
TNF-α, IL-1β, IL-2, IL-12, and IFN-γ in ear or lymph
Sur et al. BMC Complementary and Alternative Medicine  (2016) 16:38 Page 10 of 13
node tissues. In ear and auricular lymph node tissues in
our atopic animal model, Th1 cytokines were strongly
secreted, although Th2 cytokines dominated. This might
be due to a longer period of 2 % TMA challenge on both
ears (3 days longer than in Schneider’s protocol) to elicit
an intensified immune response.
As an alternative therapy, BV was injected to stimulate
a specific skin point behind the knee. The stimulation
point is located far away from the ears where allergic in-
flammation is induced by repeated exposure to TMA,
and a specific component of BV can hardly be respon-
sible for alleviation of skin symptoms. Thus, our results
demonstrate that stimulation of the specific acupoint by
BV significantly inhibited TMA-induced skin inflamma-
tion in the ears, probably due to modulation of the
systemic immune system. Although the detailed mech-
anism has not yet been elucidated, the improvement in
symptoms must be attributed to certain systemic
changes being able to affect every part of the body as
well as being triggered by local BV stimulation.
On the other side, as reported previously, BV contains
several biologically active peptides, including melittin,
apamin, and adolapin [33, 34]. Many studies indicate
that BVA can modulate a systemic immune response by
inhibiting inflammatory mediators, similar to non-
steroidal anti-inflammatory drugs (NSAIDs) [35]. Other
studies reported that BV has in vitro anti-inflammatory
activity which is ascribed to the transcriptional downreg-
ulation of NF-κB and MAPKs in target tissues [36]. One
can speculate that Th1 cytokine-based inflammatory
symptoms in atopic dermatitis were alleviated by BV
components and that this pharmacological anti-
inflammatory effect was exerted via modulation of NF-
κB and MAPK signal transduction pathways.
Since atopic dermatitis is primarily characterized by
skin symptoms such as erythema, edema, excoriation,
and scaling, we first investigated the therapeutic effects
of BVA on ear edema and thickness in our animal model
[37]. At the maximum severity of AD-like symptoms, we
started BVA treatment at a dose of 0.3 mg/kg at the
BL40 acupoints on both legs and found significant re-
ductions in ear edema and thickness 2 days after starting
BVA treatment. We thereafter confirmed that BVA treat-
ment was very effective at inhibiting activation of resi-
dent mast cells and infiltration of immune cells by
histological analysis. Because mast cells play a key role
in mediating allergic inflammation in asthma, atopic
dermatitis, and sinusitis, we also focused on changes in
mast cells in the dermis of inflamed skin. BV treatment
significantly decreased mast cell infiltration in ear tissues
[38]. Thus, it is likely that BV regulates the infiltration of
mast cells and inhibits immune cells, thereby normaliz-
ing the inflammatory response. Aggregation of FcεRI
triggers AD. After induction of AD, mast cells are
activated by crosslinking of adjacent IgE molecules [39].
Notably, IgE is responsible for both acute and chronic
symptoms in atopy-like skin diseases, and repeated in-
jection of TMA increases serum IgE levels in the mice
[40]. We found that total serum IgE levels in mice were
significantly increased by repeated TMA treatment. BV
treatment significantly reduced total serum IgE levels in
TMA-treated mice.
Many studies suggest that an imbalance between Th1
and Th2 responses is closely associated with many im-
mune disorders, including atopic dermatitis [41]. In typ-
ical allergic diseases, there are increases in the levels of
Th2 cytokines and decreases in the levels of Th1 cyto-
kines [42]. Many studies also support the assertion that
restoration of the balance between Th1 and Th2 cell
numbers, which can be achieved by either stimulation of
Th1 cell development or inhibition of Th2 cell develop-
ment, has remedial value in AD treatment [43]. How-
ever, interestingly, in our mouse model of atopy-like skin
dermatitis, in which the expression levels of both Th1
and Th2 cytokines simultaneously increased, the allevi-
ation of atopic skin symptoms by BV treatment was at-
tributed to downregulation of both Th1 and Th2
cytokines. Th2-dominated cytokine profile plays a cen-
tral role in the initiation of AD symptoms in the early
stage, and in the chronic stage of human atopic derma-
titis, cytokine profile shift from Th2 to Th1 is quite crit-
ical for aggravation of AD leading to severe dermal
inflammation. Although our atopic model of TMA-
induced hypersensitivity for 2 weeks seems to show such
a mixed profile of both Th1 and Th2 dominance and
thus be close to human chronic dermatitis of atopy, we
do not have a confidence because we did not analyze
time-course profiles of Th1- and Th-2 expression.
Local injection of BV exhibited simultaneous anti-
inflammatory and anti-allergy effects for the treatment
of atopic skin symptoms. This phenomenon might be
caused by the double-sided character of BV, as men-
tioned earlier, although we did not clearly elucidate its
mechanism in this study.
Unlike usual immunotherapies for immune diseases,
venom therapy not only induces a rapid shift in cytokine
expression from Th2 (IL-4) to Th1 (IFN-γ) cytokines,
but also leads to increased production of immunosup-
pressive cytokine IL-10 during the initial phase of the
treatment [44]. Furthermore, it was reported that al-
though low-dose BV treatment initially upregulated Th1
cytokine expression in experimental immunotherapy, ag-
gravating inflammation, pain, and scratching behavior, it
eventually relieved those symptoms [45].
In the present study, BV stimulation at a non-
acupuncture point also exhibited a significant suppres-
sive effect on TMA-induced edema formation, T-cell
activation and the levels of inflammatory cytokine
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mRNAs and proteins. It means that BV itself showed
certain levels of anti-inflammatory and anti-allergic ac-
tivities, regardless of the use of specific acupuncture
point.
Although we addressed that BVA significantly inhib-
ited the TMA-induced expression of Th2- and Th1- cy-
tokines in the present study, the detailed mechanisms of
how BVA modulated the expression levels of Th1- and
Th2-cytokines together should be elucidated in the
future.
Conclusion
In the atopy-like dermatitis mouse model, the expression
of Th2 cytokines such as IL-4, IL-5, and IL-10 in the
lymph nodes of TMA-treated mice was found to be ele-
vated, and BVA largely abrogated TMA-induced produc-
tion of Th2 cytokines. Levels of Th1 cytokines (IL-2, IL-
12, IFN-γ, and TNF-α) were also increased by TMA
treatment, and the increases were suppressed by BVA
treatment. This means that BVA significantly suppressed
the expression of both Th1 and Th2 cytokines, indicat-
ing comprehensive modulation of the Th1-Th2 balance.
Although the precise mechanism by which BV inhibits
Th2 cytokines and Th1 cytokines in our atopic mouse
model was not explicitly elucidated in this study, the re-
medial value of BV therapy might be attributed to not
only its widely known anti-inflammatory activity, but
also its strong anti-allergic activity, which we report here
for the first time.
Additional file
Additional file 1: Figure S1. Time-courses of surface temperatures at
the skin sites that BV was injected in subcutaneously, intradermally or
intramuscularly. BV (0.3 mg /kg body weight) was injected into the mid-
back after hair removal, and the temperature at the injection site in the
skin was measured using an infrared thermometer (HuBDIC Thermofinder
(FS-300), Beauty Korea World Co., Ltd., Seoul, Korea). BV injections were
performed in at least three mice, and temperature measurement was
repeated three times per injection per time point. (DOCX 42 kb)
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